| 產(chǎn)品編號 | bs-7498R-Cy5.5 |
| 英文名稱1 | Rabbit Anti-Eph receptor A1/Cy5.5 Conjugated antibody |
| 中文名稱 | Cy5.5標(biāo)記的酪氨酸蛋白激酶受體A1抗體 |
| 別 名 | EPH; EPH tyrosine kinase 1; EPH tyrosine kinase; Epha1; EPHA1_HUMAN; Ephrin receptor Eph A1; Ephrin type A receptor 1; Ephrin type-A receptor 1; EPHT 1; EPHT; EPHT1; Erythropoietin producing hepatoma amplified sequence; Erythropoietin-producing hepatoma receptor; Esk; hEpha1; MGC163163; Oncogene EPH; Soluble EPHA1 variant 1; Soluble EPHA1 variant 2; Tyrosine protein kinase receptor EPH; Tyrosine-protein kinase receptor EPH. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 通道蛋白 細(xì)胞膜受體 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Pig, Cow, Horse, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 105kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Eph receptor A1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene is expressed in some human cancer cell lines and has been implicated in carcinogenesis. [provided by RefSeq, Jul 2008] Function: The Eph family of receptors comprises the largest known family of receptor tyrosine kinases. Ligands of Eph family receptors are structurally related membrane-bound proteins that can be subdivided into two major subclasses, ephrin-A and ephrin-B. Expression of Eph receptors is tissue specific and appears to be tied to developmental events. Ligands in the ephrin-A subclass, including the prototype family member ephrin-A1 (B61), are membrane associated through glycosylphosphatidyl-inositol linkages, whereas ephrin-B subclass consists of ligands with transmembrane domains. The general role of the Eph family is in mediating repulsive cell-cell interaction. Subunit: Homodimer. Forms a signaling complex with LCK; PTK2B/PYK2 and PI3-kinase upon activation by EFNA1; regulates T-lymphocytes migration. Interacts (via SAM domain) with ILK (via ANK repeats); stimulated by EFNA1 but independent of the kinase activity of EPHA1. Interacts (kinase activity-dependent) with PTK2/FAK1. Subcellular Location: Cell membrane; Single-pass type I membrane protein Post-translational modifications: Phosphorylated. Autophosphorylation is stimulated by its ligand EFNA1. Ubiquitinated. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily. Contains 1 Eph LBD (Eph ligand-binding) domain. Contains 2 fibronectin type-III domains. Contains 1 protein kinase domain. Contains 1 SAM (sterile alpha motif) domain. Database links: Entrez Gene: 2041 Human Entrez Gene: 13835 Mouse Omim: 179610 Human SwissProt: P21709 Human SwissProt: Q60750 Mouse Unigene: 89839 Human Unigene: 133330 Mouse Unigene: 218221 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
